Literature DB >> 36271204

Oral Delivery of Nucleic Acid Therapies for Local and Systemic Action.

Neha Kumari1, Kasturi Siddhanta1, Sudipta Panja1, Vineet Joshi2, Chinmay Jogdeo1, Ekta Kapoor1, Rubayat Khan1, Sai Sundeep Kollala3, Balawant Kumar4, Diptesh Sil1, Amar B Singh4,5, Daryl J Murry2, David Oupický6.   

Abstract

Nucleic acid (NA) therapy has gained importance over the past decade due to its high degree of selectivity and minimal toxic effects over conventional drugs. Currently, intravenous (IV) or intramuscular (IM) formulations constitute majority of the marketed formulations containing nucleic acids. However, oral administration is traditionally preferred due to ease of administration as well as higher patient compliance. To leverage the benefits of oral delivery for NA therapy, the NA of interest must be delivered to the target site avoiding all degrading and inhibiting factors during its transition through the gastrointestinal tract. The oral route presents myriad of challenges to NA delivery, making formulation development challenging. Researchers in the last few decades have formulated various delivery systems to overcome such challenges and several reviews summarize and discuss these strategies in detail. However, there is a need to differentiate between the approaches based on target so that in future, delivery strategies can be developed according to the goal of the study and for efficient delivery to the desired site. The goal of this review is to summarize the mechanisms for target specific delivery, list and discuss the formulation strategies used for oral delivery of NA therapies and delineate the similarities and differences between local and systemic targeting oral delivery systems and current challenges.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  gastrointestinal diseases; local target; nucleic acids; oral delivery; systemic target

Year:  2022        PMID: 36271204     DOI: 10.1007/s11095-022-03415-7

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.580


  69 in total

Review 1.  Mechanisms of phagocytosis in macrophages.

Authors:  A Aderem; D M Underhill
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

Review 2.  Nanocarriers' entry into the cell: relevance to drug delivery.

Authors:  Hervé Hillaireau; Patrick Couvreur
Journal:  Cell Mol Life Sci       Date:  2009-06-05       Impact factor: 9.261

Review 3.  Oral delivery of non-viral nucleic acid-based therapeutics - do we have the guts for this?

Authors:  Caitriona M O'Driscoll; Andreas Bernkop-Schnürch; Julian D Friedl; Véronique Préat; Vincent Jannin
Journal:  Eur J Pharm Sci       Date:  2019-04-01       Impact factor: 4.384

Review 4.  Fomivirsen - a phosphorothioate oligonucleotide for the treatment of CMV retinitis.

Authors:  M D de Smet; C J Meenken; G J van den Horn
Journal:  Ocul Immunol Inflamm       Date:  1999-12       Impact factor: 3.070

Review 5.  Nanoparticles for oral delivery: Design, evaluation and state-of-the-art.

Authors:  Abhijit A Date; Justin Hanes; Laura M Ensign
Journal:  J Control Release       Date:  2016-06-09       Impact factor: 9.776

6.  RNA-guided human genome engineering via Cas9.

Authors:  Prashant Mali; Luhan Yang; Kevin M Esvelt; John Aach; Marc Guell; James E DiCarlo; Julie E Norville; George M Church
Journal:  Science       Date:  2013-01-03       Impact factor: 47.728

7.  Effects of fructose on synthesis and degradation of purine nucleotides in isolated rat hepatocytes.

Authors:  S Brosh; P Boer; O Sperling
Journal:  Biochim Biophys Acta       Date:  1982-08-27

Review 8.  The current landscape of nucleic acid therapeutics.

Authors:  Jayesh A Kulkarni; Dominik Witzigmann; Sarah B Thomson; Sam Chen; Blair R Leavitt; Pieter R Cullis; Roy van der Meel
Journal:  Nat Nanotechnol       Date:  2021-05-31       Impact factor: 39.213

Review 9.  Advances in the delivery of RNA therapeutics: from concept to clinical reality.

Authors:  James C Kaczmarek; Piotr S Kowalski; Daniel G Anderson
Journal:  Genome Med       Date:  2017-06-27       Impact factor: 11.117

Review 10.  The evolution of commercial drug delivery technologies.

Authors:  Ava M Vargason; Aaron C Anselmo; Samir Mitragotri
Journal:  Nat Biomed Eng       Date:  2021-04-01       Impact factor: 25.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.